BridgeBio Pharma has delivered a strong share price gain over the past three years, yet its current checks suggest the stock now looks closer to fairly valued than obviously cheap. With recent news around its ATTR-CM therapy acoramidis keeping expectations high, the question for investors is how much of that optimism is already reflected in the price.
-
The stock is up 158.6% over three years, which sets a high bar for further returns after such a strong run.
-
Progress on acoramidis, including new long term data and the ASCEND-ATTR study, can support sentiment on future cash flows, while clinical or regulatory setbacks may quickly pressure the valuation.
-
A mixed valuation score of 3 out of 6 suggests BridgeBio Pharma screens as neither a clear bargain nor clearly expensive on the broader checks.
The issue now is whether BridgeBio Pharma's current price already reflects the recent clinical progress and three year share price growth, or if there is still room for further upside on today's fundamentals.
Scan beyond BridgeBio Pharma and evaluate other potential breakouts in the same spirit of rigorous stock picking with 45 high quality undervalued stocks
Is BridgeBio Pharma Fairly Priced on Sales?
P/S is often the cleaner yardstick for BridgeBio Pharma because the company is still reporting losses and the P/E multiple is not very informative yet. Revenue gives you a clearer anchor for what the market is paying for its pipeline and its approved ATTR-CM therapy acoramidis.
BridgeBio Pharma currently trades on a P/S of about 21.0x. That is higher than the broader Biotechs industry average P/S of 13.2x and also above the peer group average of 16.4x. Acoramidis data, including upcoming presentations at ESC 2026 and the ongoing ASCEND-ATTR study, helps explain why investors are willing to pay a premium to sector norms.
The more tailored fair P/S ratio for BridgeBio Pharma, which factors in its profile and risk, is about 20.1x. That is only slightly below the current 21.0x, which indicates a premium that is present but not extreme.
Overall, BridgeBio Pharma appears roughly fairly valued on the P/S multiple, with the market already recognising much of its current ATTR-CM opportunity.
See what the numbers say about this price — find out in our valuation breakdown.
The BridgeBio Pharma Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the P/S puzzle leaves off for BridgeBio Pharma by spelling out what growth, margins and earnings path would need to hold for the current price to look meaningfully higher or lower in hindsight, based on community views. Each narrative treats BridgeBio Pharma's fair value as a thesis about the business that can be revisited over time rather than a one off snapshot.
Community views on BridgeBio Pharma are sharply split, with one side seeing significant upside potential and the other warning the stock is already pricing in a best case outcome.
Bull case: 45% undervalued
"BridgeBio's ability to leverage advances in AI-driven and genomics-driven drug discovery, validated by its rapid pipeline progress and high late-stage success rate, is positioning the company to sustain a serial product-launch model..."
Read the full Bull Case to see why BridgeBio Pharma could be undervalued
Bear case: 206% overvalued
"With Amvuttra's recent blockbuster HELIOS-B Phase 3 data, the ATTR-CM landscape is aggressively shifting from TTR stabilizers to TTR silencers..."
Read the full Bear Case to see why BridgeBio Pharma could be overvalued
Do you think there's more to the story for BridgeBio Pharma? Head over to our Community to see what others are saying!
The Bottom Line
BridgeBio Pharma now appears roughly fairly valued on its tailored P/S check rather than clearly undervalued or clearly overvalued. After such a strong three year return window, the easier money from simple rerating appears to be behind it, and the current premium leans heavily on confidence in acoramidis and the broader pipeline translating into meaningful revenue. The key question for investors is whether BridgeBio Pharma can deliver on that ATTR-CM opportunity quickly enough and with sufficient durability to keep justifying a premium P/S, or whether expectations move back closer to sector norms.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include BBIO .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
